Friday, 4 September 2026European Markets

Central Bank Policy

2 articles

ECB Faces March 19 Policy Test as 92,000 Jobs Lost, Oil Surges 36%

ECB Faces March 19 Policy Test as 92,000 Jobs Lost, Oil Surges 36%

The European Central Bank meets March 19 amid conflicting signals: February job losses hit 92,000 while oil prices jumped 36% on Iran conflict. Former Fed official Loretta Mester says central banks need 'convincing evidence' of inflation retreat before cutting rates, even as labor markets weaken.

ViaNews Editorial Team (Europe)
Fed Signals More Rate Cuts as ECB Holds Firm, Widening Atlantic Monetary Divide

Fed Signals More Rate Cuts as ECB Holds Firm, Widening Atlantic Monetary Divide

Chicago Fed President Alan Goolsbee said interest rates can drop further in 2026 if inflation moderates, contrasting with the ECB's cautious stance. The divergence pressures the euro as US markets rally on dovish Fed signals while European policymakers maintain tighter conditions. Contactless payments in Finland jumped 23% to €8.4 billion in Q2 2025 as payment infrastructure evolves.

ViaNews Editorial Team (Europe)
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Funding Surge: Capital Floods Fintech, Foundation Models, and Autonomous Systems
A concentrated burst of AI-linked funding on 2026-08-28 pushed well over $1.5B into companies spanning fraud/identity fintech (Socure, which also acquired Fravity), foundation models (Stability AI), AI agents and enterprise tooling (Instinct, Generalist AI, Emerald AI, Owner), and AI-adjacent autonomous/aerospace ventures (Gatik, Regent Craft). The breadth and simultaneity of these rounds signal that investor appetite for AI is not concentrated in a single vertical but is broadening into applied and infrastructure-adjacent domains, with consolidation (Socure-Fravity) beginning alongside fresh capital formation.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,269 source documents archived
Query this data → isubstrate.com